
| Standard Delivery (Signed for) | Delivered within 3-5 working days |
| Express Delivery (Standard Parcels) | Delivered within 1-2 working days |
| Extra-Large Parcels (Signed for) | Delivered within 3-5 working days |
| Furniture | Delivery usually takes place within 2 weeks. |
Free Shipping
Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).Drop Shipping
We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.Ground Shipping
Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.Description
DESCRIPTION
Cabergoline (brand names Dostinex and Cabaser), an ergot-derivative,
is a potent dopamine receptor agonist on D2-Receptors. It also acts on
dopamine-receptors in lactophilic hypothalamus cells and causes thereby a
suppression of the prolactin-production in pituitary gland.
Cabergoline has a very long half life, so it can be taken once or twice a week.
Pharmacokinetics
Following an oral single dose the drug is resorbed within 0.5 to 4
hours from the GI-Tract with considerable interindividual differences.
Meals do not alter the absorption characteristic. Human bioavailibility
was not determined, because the drug is intended for oral use only. In
mice and rats the absolute bioavailability was 30 and 63%, respectively.
Cabergoline is rapidly and to a great extend metabolized in the liver
and excreted in bile and far less in urine. All metabolites are less
active than the parental drug or inactive. The human elimination
halflife is estimated to be 63 to 68 hours in patients with M. Parkinson
and 79 to 115 hours in patients with pituitary tumors.
Carcinogenity
In rodents a dose dependent increase in malignant tumors has been
found. They are thought to be species-specific. No clinical data exists
on carcinogenity in humans.
Off-Label/Recreational Uses
It has at times been used as an adjunct to SSRI antidepressants as
there is some evidence that it counteracts certain side effects of those
drugs such as reduced libido and anorgasmia. It also has been suggested
online that it has a possible recreational use in reducing or
eliminating the male refractory period.
Side effects
Approximately 200 patients with newly diagnostizised M. Parkinson
participated in a clinical study regarding the monotherapy with
cabergoline. Seventynine (79) % reported at least one side effect. These
side effects were chiefly mild or moderate:
GI-Tract: Side effects were extremly frequent. Fiftythree Per Cent of
patients reported side effects. Nausea (30%), obstipation (22%), and dry
mouth (10%) were very frequent. Frequent were gastric irritation (7%),
vomiting (5%), and dyspepsia (2%).
Psychiatric Disturbances and CNS: Altogether 51% of patients were
affected. Very frequent were disturbances of sleep (somnolence 18%,
insomnia 11%), vertigo (27%), and depression (13%). Frequent were
dyskinesia (4%) and hallucinations (4%).
Cardiovascular: Approximately 30% of patients experienced side effects.
Most frequent were hypotension (10%), peripheral edema (14%) and
non-specific edema (2%). Arrhythmias were encountered in 4.8%,
palpitations in 4.3%, and angina pectoris in 1.4%.
In a combination study with 2,000 patients also treated with levodopa
the incidence and severity of side effects was comparable to
monotherapy. Encountered side effects required a termination of
cabergoline treatment in 15% of patients. Additional side effects were
infrequent cases of hematological side effects, and an occasional
increase in liver enzymes or serum creatinine without signs or symptoms.
As with other ergot-derivatives pleuritis, exsudative pleura disease,
pleura fibrosis, lung fibrosis, and pericarditis are seen. These side
effects are noted in less than 2% of patients. They require immediate
termination of treatment. Clinical improvement and normalization of
X-Ray findings are normally seen soon after cabergoline withdrawal.
The reported incidence and severity of side effects in hyperprolactinemic patients was comparable.